An HIV/VL patient’s long road to better treatment

Man sitting on a bed in a hospital

Nigatu Abebe from Ethiopia sits on a bed in the Leishmaniasis Research and Treatment Centre (LRTC) at the University of Gondar in Ethiopia. He looks very frail and has been battling against visceral leishmaniasis (VL), also known as kala-azar, and HIV for 11 years.

2018 in Review

Dr Kande in DRC screening patients in a village

2018 showed us that another way to develop life-saving drugs is possible. Travel the globe with us to see how 15 years of patient-focused research and development (R&D) are bearing fruit for the most neglected patients.

Making Medical History

More than 180 friends, supporters, partners, celebrities, and global health influencers celebrated our 15-year anniversary with us at our Making Medical History Gala in New York City.

Inaugural DNDi training for health & science journalists in Kampala

In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted during a week of workshops and meetings related to the work of DNDi and its many partners, culminating in the 11th DNDi Partners’ Meeting on 4 October 2018.

Malaysia takes the lead on a public health approach to hepatitis C with new initiative to enhance diagnosis & treatment

Doctor in a hospital in Malaysia

New agreement between Clinical Research Malaysia & FIND on R&D for hepatitis C diagnostic tests continues an existing Malaysian partnership with DNDi for hepatitis C treatment

The Foundation for Innovative New Diagnostics (FIND) and Clinical Research Malaysia (CRM), both DNDi partners, recently signed a memorandum of understanding (MoU) to collaborate in the research and development of an innovative hepatitis C diagnostic testing strategy.

DNDi announces new Director of Neglected Tropical Diseases

Dr Nathalie Strub-Wourgaft examines patient in Sudan.

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

भारत में काला आज़ार के बाद डर्मल लेशमेनियासिस

लौटकर पलटवार करती बीमारीक्या लेशमेनियासिस का एक प्रकार भारत मे उन्मूलन प्रयासों के लिए चुनौती बन सकता है? रूबी देवी ने जब भारत के सबसे गरीब राज्य बिहार से देश की राजधानी का रूख किया तो उन्हें लगा कि विसरल लेशमेनियासिस के साथ चल रही उनकी आज़माइश अब पूरी हुई | विसरल लेशमेनियासिस जिसे भारत […]

Revealing the Neglect: Chagas Disease

Yerko grew up in Bolivia in the small community of El Forestal in the east of the country. As a child, he and his family lived in a house with walls made of adobe bricks and a roof of palm leaves. Hidden inside the cracks and crevices in the walls and roof were kissing bugs. Yerko wanted to become a pharmacist to help people in need, but became a victim of Chagas disease.

Revealing the Neglect: River Blindness

“It just went completely white.” This is the how fisherman Akoyo Osumaka describes going blind in 2011, in the remote village of Babagulu in the Democratic Republic of Congo (DRC). It was a slow, creeping blindness that began a year earlier. It robbed him of his livelihood and threw his family life into disarray.

DNDi welcomes Astellas to the NTD Drug Discovery Booster

Scientist holding a test tube

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Medical staff looking into a microscope while screening patients in DRC

Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.

R&D Portfolio Update March 2018: DNDi Leishmaniasis programme

VL patient under treatment in Sadar Hospital Chapra

Three new chemical entities entered the pre-clinical pipeline, bringing to six the number of new compounds progressing in the leishmaniasis portfolio, with two already nominated as clinical candidates to progress to Phase I. The first patient was recruited in India in Phase II studies to test new treatments for PKDL, while clinical sites were being prepared in Bangladesh and Sudan. A site was initiated in Sudan for a Phase III study to test a new combination treatment for leishmaniasis in the African region. In Latin America, a Phase II study on new combination treatments for cutaneous leishmaniasis progressed well.

R&D Portfolio Update March 2018: DNDi Chagas disease programme

Young girl holding a flyer on Chagas disease

Two Phase II trials are ongoing, with the study in Bolivia on benznidazole for improved treatment of chronic indeterminate Chagas disease having completed recruitment at the end of 2017, and a study in Spain in the early stages of patient recruitment to evaluate fexinidazole as Chagas treatment. A pilot project to increase access to diagnosis and treatment in five endemic communities in Colombia showed excellent interim results and will report one-year results in mid-2018. In 2018, DNDi and Fundación Mundo Sano will launch a new Chagas Disease Regional Access Framework.